Eli Lilly and Company

🇺🇸New York Stock Exchange
Back to all articles
Eli Lilly and Company stock analysis LLY overview
Bullish +65

Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow - 24/7 Wall St.

📈 Eli Lilly reported Q1 2026 revenue of $19.80B, representing a 55.5% year-over-year increase.

💊 Mounjaro contributed $8.66B to Lilly's revenue, reflecting a 125% jump in sales.

📉 Realized prices for Lilly's obesity drugs fell 13% as the company prioritizes volume growth and market share expansion.

🚀 Pfizer acquired Metsera for roughly $7B to integrate ultra-long-acting obesity assets into its pipeline.

💰 Pfizer's revenue grew 5.4% to $14.45B, driven by Eliquis (+13%) and Padcev (+39%).

📉 Pfizer saw significant declines in COVID products, with Comirnaty falling 59% and Paxlovid dropping 62%.

✅ Lilly received FDA approval for Foundayo, the first oral GLP-1 pill without food or water restrictions.

⏳ Pfizer extended Vyndamax patent exclusivity to June 2031 via a settlement with US authorities.

📊 Analysts target a stock price of $1,215.79 for Eli Lilly based on its strong growth trajectory.

💸 Pfizer offers a 6.61% dividend yield and trades at a forward PE ratio around 9.

Bullish Signals
  • Lilly's revenue surged 55.5% to $19.80B, demonstrating exceptional growth in the obesity drug sector.
  • Mounjaro sales jumped 125% to $8.66B, solidifying Lilly's leadership in the GLP-1 market.
  • Lilly achieved a 65% volume increase while strategically accepting lower prices to secure market dominance.
  • Pfizer successfully extended Vyndamax patent exclusivity to June 2031, mitigating future revenue cliffs.
  • Lilly's Foundayo received FDA approval as the first oral GLP-1 pill without food or water restrictions.
  • Pfizer's Padcev sales surged 39%, contributing significantly to its overall revenue growth.
  • Analysts maintain a high price target of $1,215.79 for Lilly, reflecting confidence in its business model.
Risk Factors
  • Lilly's realized prices fell 13% as the company prioritizes volume over pricing power in the obesity market.
  • Pfizer faces a significant revenue decline in COVID-related products, with Comirnaty down 59% and Paxlovid down 62%.
  • Shares of Lilly cooled by 5.37% in the past week despite a 40.92% one-year gain, indicating stretched expectations.
  • Pfizer's $7B acquisition of Metsera requires successful Phase 3 data to justify the substantial spend.
Full Analysis
Eli Lilly (LLY) and Pfizer (PFE) reported contrasting Q1 2026 results, with Lilly dominating the obesity market while Pfizer rebuilds post-pandemic. Lilly generated $19.80B in revenue, a 55.5% increase driven by Mounjaro ($8.66B) and Zepbound ($4.16B), achieving a 65% volume rise despite a 13% price decline to capture market share. Pfizer reported $14.45B in revenue, up 5.4%, supported by Eliquis ($2.17B) and Padcev (up 39%), though it faced significant declines in COVID-related products like Comirnaty (-59%) and Paxlovid (-62%). The company recently acquired Metsera for approximately $7B to bolster its obesity pipeline, which now includes around 20 pivotal study starts. Strategic differences define the two companies: Lilly secured FDA approval for Foundayo, the first oral GLP-1 pill without food or water restrictions, while Pfizer extended Vyndamax patent exclusivity to June 2031. Valuation metrics diverge sharply, with Lilly trading at a forward PE near 31 and analysts targeting $1,215.79, whereas Pfizer trades at a forward PE around 9 with a 6.61% dividend yield.